were used by 78 per cent of children and 86 per cent of infants in the trial.GSK said that, if it gets the green light for RTS,S, the vaccine would probably be distributed through agencies such as Unicef and the GAVI Alliance, a public-private health partnership.The price would cover the cost of manufacturing plus a margin of five per cent which would be ploughed into research for next-generation